Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system
Abstract Background Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiovascular-induced adverse events such as heart failure, hypertension, isc...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | Cardio-Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40959-023-00184-z |
| _version_ | 1797451319040016384 |
|---|---|
| author | Abdulrazaq S. Al-Jazairi Nahlah Bahammam Dhai Aljuaid Lama Almutairi Shroog Alshahrani Norah Albuhairan Peter M. B. Cahusac Ghazwa B. Korayem |
| author_facet | Abdulrazaq S. Al-Jazairi Nahlah Bahammam Dhai Aljuaid Lama Almutairi Shroog Alshahrani Norah Albuhairan Peter M. B. Cahusac Ghazwa B. Korayem |
| author_sort | Abdulrazaq S. Al-Jazairi |
| collection | DOAJ |
| description | Abstract Background Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiovascular-induced adverse events such as heart failure, hypertension, ischemic heart disease, arrhythmias, thromboembolic events, and hemorrhage remain a major complication. The European society of cardiology address that concern with antineoplastic monoclonal antibodies issuing a guideline to manage and monitor chemotherapy-induced cardiotoxicity. There is limited evidence of the real-world prevalence of cardiovascular (CV) events induced by monoclonal antibodies among patients with cancer in Saudi Arabia. Objective To evaluate the prevalence of cardiovascular adverse events among patients with cancer treated with monoclonal antibodies in Saudi Arabia. Methods This is a retrospective study conducted in a tertiary care hospital, Riyadh, Saudi Arabia. Data were obtained from an electronic medical record of patients with cancer treated with one of the selected monoclonal antibodies, who met the inclusion criteria between January 2005 until June 2015 and have been followed up for at least one year. Patients were stratified into groups according to monoclonal antibodies treatment: trastuzumab, bevacizumab, pertuzumab, and combined mAbs. Results A total of 1067 patient were included in the study, within the pre-determined study period. The prevalence of cardiovascular disease among patients with cancer treated with monoclonal antibodies was 16.3%. The prevalence of heart failure was relatively higher in the trastuzumab group (46/626 patients, 7.3%). Among 418 patients treated with bevacizumab, hypertension was the most frequent adverse event, reported in 38 patients (9.1%), followed by thromboembolism reported in 27 patients (6.5%). Treatment discontinuation owing to cardiovascular adverse events was reported in 42/1,067 patients (3.9%). Conclusion and relevance Prevalence of antineoplastic monoclonal antibody induced cardiovascular adverse events among patients with cancer is substantially high in Saudi Arabia. There is an urgent need to streamline the practice for identifying high risk patients and flexible referral system for cardio-oncology care. |
| first_indexed | 2024-03-09T14:51:58Z |
| format | Article |
| id | doaj.art-2070aba6185a46ecbe47fd29779da29b |
| institution | Directory Open Access Journal |
| issn | 2057-3804 |
| language | English |
| last_indexed | 2024-03-09T14:51:58Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardio-Oncology |
| spelling | doaj.art-2070aba6185a46ecbe47fd29779da29b2023-11-26T14:22:36ZengBMCCardio-Oncology2057-38042023-09-019111110.1186/s40959-023-00184-zCardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare systemAbdulrazaq S. Al-Jazairi0Nahlah Bahammam1Dhai Aljuaid2Lama Almutairi3Shroog Alshahrani4Norah Albuhairan5Peter M. B. Cahusac6Ghazwa B. Korayem7Division of Clinical Trials Transformation Initiative, King Faisal Specialist Hospital & Research CentreCollege of Pharmacy, Princess Nourah Bint Abdulrahman UniversityCollege of Pharmacy, Princess Nourah Bint Abdulrahman UniversityCollege of Pharmacy, Princess Nourah Bint Abdulrahman UniversityCollege of Pharmacy, Princess Nourah Bint Abdulrahman UniversityKing Faisal Specialist Hospital & Research CentreCollege of Pharmacy and Medicine, Alfaisal UniversityDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman UniversityAbstract Background Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiovascular-induced adverse events such as heart failure, hypertension, ischemic heart disease, arrhythmias, thromboembolic events, and hemorrhage remain a major complication. The European society of cardiology address that concern with antineoplastic monoclonal antibodies issuing a guideline to manage and monitor chemotherapy-induced cardiotoxicity. There is limited evidence of the real-world prevalence of cardiovascular (CV) events induced by monoclonal antibodies among patients with cancer in Saudi Arabia. Objective To evaluate the prevalence of cardiovascular adverse events among patients with cancer treated with monoclonal antibodies in Saudi Arabia. Methods This is a retrospective study conducted in a tertiary care hospital, Riyadh, Saudi Arabia. Data were obtained from an electronic medical record of patients with cancer treated with one of the selected monoclonal antibodies, who met the inclusion criteria between January 2005 until June 2015 and have been followed up for at least one year. Patients were stratified into groups according to monoclonal antibodies treatment: trastuzumab, bevacizumab, pertuzumab, and combined mAbs. Results A total of 1067 patient were included in the study, within the pre-determined study period. The prevalence of cardiovascular disease among patients with cancer treated with monoclonal antibodies was 16.3%. The prevalence of heart failure was relatively higher in the trastuzumab group (46/626 patients, 7.3%). Among 418 patients treated with bevacizumab, hypertension was the most frequent adverse event, reported in 38 patients (9.1%), followed by thromboembolism reported in 27 patients (6.5%). Treatment discontinuation owing to cardiovascular adverse events was reported in 42/1,067 patients (3.9%). Conclusion and relevance Prevalence of antineoplastic monoclonal antibody induced cardiovascular adverse events among patients with cancer is substantially high in Saudi Arabia. There is an urgent need to streamline the practice for identifying high risk patients and flexible referral system for cardio-oncology care.https://doi.org/10.1186/s40959-023-00184-zMonoclonal antibodiesCardiovascular diseaseTrastuzumabBevacizumabPertuzumabCardiovascular adverse event |
| spellingShingle | Abdulrazaq S. Al-Jazairi Nahlah Bahammam Dhai Aljuaid Lama Almutairi Shroog Alshahrani Norah Albuhairan Peter M. B. Cahusac Ghazwa B. Korayem Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system Cardio-Oncology Monoclonal antibodies Cardiovascular disease Trastuzumab Bevacizumab Pertuzumab Cardiovascular adverse event |
| title | Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system |
| title_full | Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system |
| title_fullStr | Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system |
| title_full_unstemmed | Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system |
| title_short | Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system |
| title_sort | cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients real world evidence from a tertiary healthcare system |
| topic | Monoclonal antibodies Cardiovascular disease Trastuzumab Bevacizumab Pertuzumab Cardiovascular adverse event |
| url | https://doi.org/10.1186/s40959-023-00184-z |
| work_keys_str_mv | AT abdulrazaqsaljazairi cardiovascularadverseeventsofantineoplasticmonoclonalantibodiesamongcancerpatientsrealworldevidencefromatertiaryhealthcaresystem AT nahlahbahammam cardiovascularadverseeventsofantineoplasticmonoclonalantibodiesamongcancerpatientsrealworldevidencefromatertiaryhealthcaresystem AT dhaialjuaid cardiovascularadverseeventsofantineoplasticmonoclonalantibodiesamongcancerpatientsrealworldevidencefromatertiaryhealthcaresystem AT lamaalmutairi cardiovascularadverseeventsofantineoplasticmonoclonalantibodiesamongcancerpatientsrealworldevidencefromatertiaryhealthcaresystem AT shroogalshahrani cardiovascularadverseeventsofantineoplasticmonoclonalantibodiesamongcancerpatientsrealworldevidencefromatertiaryhealthcaresystem AT norahalbuhairan cardiovascularadverseeventsofantineoplasticmonoclonalantibodiesamongcancerpatientsrealworldevidencefromatertiaryhealthcaresystem AT petermbcahusac cardiovascularadverseeventsofantineoplasticmonoclonalantibodiesamongcancerpatientsrealworldevidencefromatertiaryhealthcaresystem AT ghazwabkorayem cardiovascularadverseeventsofantineoplasticmonoclonalantibodiesamongcancerpatientsrealworldevidencefromatertiaryhealthcaresystem |